Anti-TNF agents for the treatment of spondyloarthropathies.

about

Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis.Adalimumab for the treatment of ankylosing spondylitis.

P2860

Q34292245-21FCE299-E993-4C3F-8BCE-3282B4705582 Q42616837-B53DA5FD-C98A-4D7B-ACAC-8C4211F2C6AB

P2860

Anti-TNF agents for the treatment of spondyloarthropathies.

Item

http://www.wikidata.org/entity/Q40409369

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Anti-TNF agents for the treatment of spondyloarthropathies.

@en

type

Item

label

Anti-TNF agents for the treatment of spondyloarthropathies.

@en

prefLabel

Anti-TNF agents for the treatment of spondyloarthropathies.

@en

P1476

Anti-TNF agents for the treatment of spondyloarthropathies.

@en

P2093

Joachim Sieper

http://www.w3.org/2001/XMLSchema#string

Jürgen Braun

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromsø, northern Norway

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Multicentric reticulohistiocytosis: case report with immunohistochemical analysis and literature review.

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

P304

235-246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.7.2.235

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15989547

http://www.w3.org/2001/XMLSchema#string

P921

TNF inhibitor

Anti-TNF agents for the treatment of spondyloarthropathies.

about

P2860

P2860

Anti-TNF agents for the treatment of spondyloarthropathies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921